ISRCTN32017426已完成未知
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART): a randomised controlled trial
The University of Dundee (UK)0 个研究点目标入组 5,937 人开始时间: 2013年8月16日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 5,937
研究概览
简要总结
2016 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/27609859 protocol 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36216006/ (added 11/10/2022) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38551218/ (added 03/04/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female patients aged 60 years and over
- •2. Ischaemic heart disease (IHD) defined as a diagnosis of angina or myocardial infarction (MI) at any time or other evidence ofischaemic heart disease (investigator opinion)
排除标准
- •1. History of gout
- •2. Known severe renal impairment (eGFR <30ml/min)
- •3. Moderate to severe heart failure (NYHA III-IV)
- •4. Significant hepatic disease (eg ALT >3 x upper limit of normal, cirrhosis, ascites) (investigator opinion)
- •5. Patients currently taking part in another interventional clinical trial of an investigational medicinal product or medical device (or taken part in one within the last 3 months)
- •6. Previous allergy to allopurinol
- •7. Previous serious adverse cutaneous (skin) reaction to any drug (eg Stevens Johnson syndrome, toxic epidermal necrolysis, hospitalisation due to skin reaction to drug) (investigator opinion)
- •8. Patients already taking urate lowering therapy (including allopurinol, febuxostat, sulfinpyrazone, benzbromarone, probenecid, rasburicase)
- •9. Patients taking azathioprine, mercaptopurine, ciclosporin or theophylline
- •10. Malignancy (except non-metastatic, non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years (investigator opinion)
研究者
相似试验
进行中（未招募）
不适用
Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART)Ischaemic Heart Disease (IHD), angina or myocardial infarctionMedDRA version: 16.0Level: LLTClassification code 10023024Term: Ischaemic heart diseaseSystem Organ Class: 100000004849EUCTR2013-003559-39-GBThe University of Dundee5,215
进行中（未招募）
不适用
The APEX Trial: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients with Cardiac Syndrome X - APEX studyEUCTR2007-002293-54-GBniversity of Dundee40
招募中
3 期
CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass100103941000751010010335Brain injuryNL-OMON52736niversitair Medisch Centrum Utrecht236
招募中
3 期
CeRebrUm and CardIac protection with ALlopurinol in Neonates with Critical Congenital Heart Disease requiring Cardiac Surgery with Cardiopulmonary Bypass2024-513041-37-00Universitair Medisch Centrum Utrecht236
进行中（未招募）
1 期
CeRebrUm and CardIac protection with ALlopurinol in Neonates with Critical Congenital Heart Disease requiring Cardiac Surgery with Cardiopulmonary BypassBrain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.MedDRA version: 21.1Level: PTClassification code: 10067967Term: Brain injury Class: 100000004852MedDRA version: 20.0Level: LLTClassification code: 10010495Term: Congenital heart disease NOS Class: 10010331CTIS2024-513041-37-00niversitair Medisch Centrum Utrecht236